Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry
Publication
, Conference
Abonour, R; Durie, B; Jagannath, S; Shah, J; Narang, M; Terebelo, H; Gasparetto, C; Toomey, K; Hardin, J; Kitali, A; Gibson, CJ; Srinivasan, S ...
Published in: Clinical Lymphoma Myeloma and Leukemia
February 2017
Duke Scholars
Published In
Clinical Lymphoma Myeloma and Leukemia
DOI
ISSN
2152-2650
Publication Date
February 2017
Volume
17
Issue
1
Start / End Page
e89 / e90
Publisher
Elsevier BV
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Abonour, R., Durie, B., Jagannath, S., Shah, J., Narang, M., Terebelo, H., … Rifkin, R. (2017). Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry. In Clinical Lymphoma Myeloma and Leukemia (Vol. 17, pp. e89–e90). Elsevier BV. https://doi.org/10.1016/j.clml.2017.03.160
Abonour, Rafat, Brian Durie, Sundar Jagannath, Jatin Shah, Mohit Narang, Howard Terebelo, Cristina Gasparetto, et al. “Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry.” In Clinical Lymphoma Myeloma and Leukemia, 17:e89–90. Elsevier BV, 2017. https://doi.org/10.1016/j.clml.2017.03.160.
Abonour R, Durie B, Jagannath S, Shah J, Narang M, Terebelo H, et al. Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. e89–90.
Abonour, Rafat, et al. “Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry.” Clinical Lymphoma Myeloma and Leukemia, vol. 17, no. 1, Elsevier BV, 2017, pp. e89–90. Crossref, doi:10.1016/j.clml.2017.03.160.
Abonour R, Durie B, Jagannath S, Shah J, Narang M, Terebelo H, Gasparetto C, Toomey K, Hardin J, Kitali A, Gibson CJ, Srinivasan S, Swern A, Rifkin R. Health-Related Quality of Life (HRQoL) of Patients (pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Any or Lenalidomide (LEN) Maintenance After Autologous Stem Cell Transplant (ASCT) in the Connect® MM Disease Registry. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. e89–e90.
Published In
Clinical Lymphoma Myeloma and Leukemia
DOI
ISSN
2152-2650
Publication Date
February 2017
Volume
17
Issue
1
Start / End Page
e89 / e90
Publisher
Elsevier BV
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences